Form 8-K - Current report:
SEC Accession No. 0001213900-24-047151
Filing Date
2024-05-28
Accepted
2024-05-28 17:23:08
Documents
14
Period of Report
2024-05-23
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0206971-8k_emmaus.htm   iXBRL 8-K 27874
2 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS ea020697101ex3-1_emmaus.htm EX-3.1 4870
  Complete submission text file 0001213900-24-047151.txt   205471

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE emma-20240523.xsd EX-101.SCH 3030
4 XBRL LABEL FILE emma-20240523_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE emma-20240523_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0206971-8k_emmaus_htm.xml XML 3476
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 24993100
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)